Patent intelligence · US
US 2025295738
Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin
Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin
Patent details — US 2025295738
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 25, 2025
- Expiration
- Sep 20, 2045
- CPC classes
- A61K 38/ 27 A I, A61K/3827, A61P 5/ 06 A I, A61P/506
Quick answer
US 2025295738 (Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin) is held by ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK]. Status: granted. Granted Sep 25, 2025. Expires Sep 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 27 A I, A61K/3827, A61P 5/ 06 A I, A61P/506
Frequently asked questions
What is US patent 2025295738?
US 2025295738 (Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin) is held by ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK]. Status: granted. Granted Sep 25, 2025. Expires Sep 20, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2025295738?
ASCENDIS PHARMA ENDOCRINOLOGY DIV A/S [DK] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 2025295738 expire?
Our index shows an expiration date of Sep 20, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.